ESC 365 - Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes

ESC Premium Access

Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes

Session: Lipid-lowering therapy: old faces and new issues

Topic: Lipids (Epidemiology and Prevention)

Speaker: Doctor K. Koskinas (Bern, CH)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Konstantinos Koskinas

Bern University Hospital, Inselspital, Bern (Switzerland)

16 presentations

25 followers

6 more presentations in this session

Statin use among HIV-infected adults by cardiovascular disease risk status

Speaker: Doctor R. Rosenson (New York, US)

Adipose tissue content of alpha-linolenic acid and the risk of ischemic stroke - A danish case-cohort study

Speaker: Mr C. Bork (Aalborg, DK)

Low density lipoprotein cholesterol levels at first follow-up after acute myocardial infarction predicts recurrent atherosclerotic cardiovascular disease events poorly.

Speaker: Doctor J. Ohm (Stockholm, SE)

Significant correlation of vascular and haematopoietic tissue FDG uptake in genetic dyslipidaemia sub-types

Speaker: Doctor G. Benetos (Athens, GR)

Low LDL-cholesterol goal attainment 4 months after ACS due to lack of adjustment in lipid lowering treatment: Results from DYSIS II

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Access the full session

Lipid-lowering therapy: old faces and new issues

Speakers: Doctor K. Koskinas, Doctor R. Rosenson, Mr C. Bork, Doctor J. Ohm, Doctor G. Benetos...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources